P. aeruginosa is a highly drug-resistant pathogen. In the drug’s pre-clinical trials, it was able to both prevent and treat pneumonia caused by P. aeruginosa in animal models. The drug, MEDI3902, could be used as a therapeutic approach to control pneumonia in hospital patients.
The Fast Track program is designed to facilitate the development and expedite the review of new drugs to treat serious conditions and fill an unmet need.
“The Fast Track designation will streamline communications with the FDA throughout the development process on what is a very different approach to the bacterial resistance problem,” said Steve Projan, PhD, senior vice president of R&D and infectious diseases & vaccines for MedImmune. “If successful, we hope to bring this important new medicine to patients as quickly as possible.”
More articles on infection control:
Cases of rare respiratory virus confirmed in 27 states
LA BioMed receives NIH grant to study HAI vaccines
Top 10 infection control stories, September 15-19
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.